The DOI matches its Crossref record; 70 of the 75 references it cites were found in a registry or an index.
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
Abstract
The oxycyclohexyl acid BMS-986278 ( 33 ) is a potent lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, with a human LPA 1 K b of 6.9 nM. The structure–activity relationship (SAR) studies starting from the LPA 1 antagonist clinical compound BMS-986020 ( 1 ), which culminated in the discovery of 33, are discussed. The detailed in vitro and in vivo preclinical pharmacology profiles of 33, as well as its pharmacokinetics/metabolism profile, are described. On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclinical species, 33 was advanced into clinical trials, including an ongoing Phase 2 clinical trial in patients with lung fibrosis (NCT04308681).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [105]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry
Chinchilla, R., & Nájera, C. (2007) · Chemical Reviews · doi:10.1021/cr050992x · Cited by 2,974
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Ishiyama, T., Murata, M., & Miyaura, N. (1995) · The Journal of Organic Chemistry · doi:10.1021/jo00128a024 · Cited by 1,590
Mitsunobu and Related Reactions: Advances and Applications
Swamy, K. C. K., Kumar, N. N. B., Balaraman, E., & Kumar, K. V. P. P. (2009) · Chemical Reviews · doi:10.1021/cr800278z · Cited by 1,184
Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides
Zhang, L., Chen, X., Xue, P., Sun, H. H. Y., Williams, I. D., Sharpless, K. B., Fokin, V. V., & Jia, G. (2005) · Journal of the American Chemical Society · doi:10.1021/ja054114s · Cited by 1,120
Self-citationRitchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Bile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
Cottin, V., Hirani, N. A., Hotchkin, D. L., Nambiar, A. M., Ogura, T., Otaola, M., Skowasch, D., Park, J. S., Poonyagariyagorn, H. K., Wuyts, W., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0076-2018 · Cited by 652
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, T., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 636
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., & Esser, D. (2012) · European Respiratory Review · doi:10.1183/09059180.00002512 · Cited by 552
Lattouf, R., Younes, R., Lutomski, D., Naaman, N., Godeau, G., Senni, K., & Changotade, S. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414545787 · Cited by 511
Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors
Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J., Kimura, T., Tobo, M., Yamazaki, Y., Watanabe, T., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.4.994 · Cited by 402
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Fibrosing interstitial lung diseases: knowns and unknowns
Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0100-2018 · Cited by 336
Ruthenium-Catalyzed Cycloaddition of Aryl Azides and Alkynes
Rasmussen, L. K., Boren, B. C., & Fokin, V. V. (2007) · Organic Letters · doi:10.1021/ol701912s · Cited by 327
Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies
Geraldo, L. H. M., Spohr, T. C. L. D. S., Amaral, R. F. D., Fonseca, A. C. C. D., Garcia, C., Mendes, F. D. A., Freitas, C., dosSantos, M. F., & Lima, F. R. S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00367-5 · Cited by 313
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295
GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures
Shimada, I., Ueda, T., Kofuku, Y., Eddy, M. T., & Wüthrich, K. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.180 · Cited by 279
A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
Swaney, J., Chapman, C., Correa, L., Stebbins, K., Bundey, R., Prodanovich, P., Fagan, P., Baccei, C., Santini, A., Hutchinson, J., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00828.x · Cited by 261
Physiology of the lung in idiopathic pulmonary fibrosis
Plantier, L., Cazes, A., Dinh-Xuan, A.-T., Bancal, C., Marchand-Adam, S., & Crestani, B. (2018) · European Respiratory Review · doi:10.1183/16000617.0062-2017 · Cited by 259
Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Ahluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1
Chrencik, J. E., Roth, C. B., Terakado, M., Kurata, H., Omi, R., Kihara, Y., Warshaviak, D., Nakade, S., Asmar-Rovira, G., Mileni, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.002 · Cited by 204
Palmer, S. M., Snyder, L., Todd, J. L., Soule, B., Christian, R., Anstrom, K., Luo, Y., Gagnon, R., & Rosen, G. (2018) · Chest · doi:10.1016/j.chest.2018.08.1058 · Cited by 202
Self-citationFurther concerns over Cheng-Prusoff analysis
Leff, P., & Dougall, I. G. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90080-4 · Cited by 185
Drugs and hepatic transporters: A review
Jetter, A., & Kullak-Ublick, G. A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.018 · Cited by 175
Simon, J., Salzbrunn, S., Surya Prakash, G. K., Petasis, N. A., & Olah, G. A. (2001) · The Journal of Organic Chemistry · doi:10.1021/jo0015873 · Cited by 163
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01487-0 · Cited by 161
Swaney, J. S., Chapman, C. W., Correa, L. D., Stebbins, K. J., Broadhead, A. R., Bain, G., Santini, A. M., Darlington, J. V., King, C. D., Baccei, C. S., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175901 · Cited by 146
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Collins, B. F., & Raghu, G. (2019) · European Respiratory Review · doi:10.1183/16000617.0022-2019 · Cited by 137
Alam, K., Crowe, A., Wang, X., Zhang, P., Ding, K., Li, L., & Yue, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030855 · Cited by 132
Kenna, J. G., Taskar, K. S., Battista, C., Bourdet, D. L., Brouwer, K. L. R., Brouwer, K. R., Dai, D., Funk, C., Hafey, M. J., Lai, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1222 · Cited by 130
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 127
Allanore, Y., Distler, O., Jagerschmidt, A., Illiano, S., Ledein, L., Boitier, E., Agueusop, I., Denton, C. P., & Khanna, D. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40547 · Cited by 113
Kianmehr, E., Yahyaee, M., & Tabatabai, K. (2007) · Tetrahedron Letters · doi:10.1016/j.tetlet.2007.02.069 · Cited by 113
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
Woodhead, J. L., Yang, K., Siler, S. Q., Watkins, P. B., Brouwer, K. L. R., Barton, H. A., & Howell, B. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00240 · Cited by 98
Shea, B. S., & Tager, A. M. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-005aw · Cited by 95
A rat G protein‐coupled receptor selectively expressed in myelin‐forming cells
Allard, J., Barrón, S., Díaz, J., Lubetzki, C., Zalc, B., Schwartz, J., & Sokoloff, P. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00117.x · Cited by 92
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Yoon, H., Park, S., Kim, D. S., & Song, J. W. (2018) · Respiratory Research · doi:10.1186/s12931-018-0907-8 · Cited by 81
Lung Section Staining and Microscopy
Zhou, X., & Moore, B. (2017) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2286 · Cited by 77
Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox
Llona‐Minguez, S., Ghassemian, A., & Helleday, T. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.004 · Cited by 66
Zhang, M., Wang, X., Yang, H., Fogo, A. B., Murphy, B. J., Kaltenbach, R. F. I., Cheng, P., Zinker, B. A., & Harris, R. C. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017010107 · Cited by 60
Self-citationZhang, J., He, K., Cai, L., Chen, Y., Yang, Y., Shi, Q., Woolf, T. F., Ge, W., Guo, L., Borlak, J. T., et al. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.03.019 · Cited by 49
Self-citationSmith, M. J. P., Lawler, M. J., Kopp, N., McLeod, D. D., Davulcu, A. H., Lin, D., Katipally, K. R., & Sfouggatakis, C. (2017) · Organic Process Research & Development · doi:10.1021/acs.oprd.7b00301 · Cited by 47
Di Martino, E., Provenzani, A., Vitulo, P., & Polidori, P. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020964451 · Cited by 46
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Raghu, G. (2017) · European Respiratory Review · doi:10.1183/16000617.0071-2017 · Cited by 45
Lysophosphatidic Acid (LPA) Induces Plasma Exudation and Histamine Release in Mice via LPA Receptors
Hashimoto, T., Ohata, H., & Honda, K. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fpj05030x · Cited by 42
Aleo, M. D., Shah, F., He, K., Bonin, P. D., & Rodrigues, A. D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00048 · Cited by 42
Signalling by lysophosphatidate and its health implications
Hemmings, D. G., & Brindley, D. N. (2020) · Essays in Biochemistry · doi:10.1042/ebc20190088 · Cited by 39
Vieira, M. D. L. T., & Tagliati, C. A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.884069 · Cited by 38
New perspectives on management of idiopathic pulmonary fibrosis
Puglisi, S., Torrisi, S. E., Vindigni, V., Giuliano, R., Palmucci, S., Mulè, M., & Vancheri, C. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315624276 · Cited by 38
Allanore, Y., Distler, O., Jagerschmidt, A., Illiano, S., Ledein, L., Boitier, E., Agueusop, I., Denton, C. P., & Khanna, D. (2018) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-151637 · Cited by 38
Yucha, R. W., He, K., Shi, Q., Cai, L., Nakashita, Y., Xia, C. Q., & Liao, M. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx060 · Cited by 35
Ledein, L., Léger, B., Dees, C., Beyer, C., Distler, A., Vettori, S., Boukaiba, R., Bidouard, J., Schaefer, M., Pernerstorfer, J., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15190 · Cited by 35
Morphological Methods for Assessment of Fibrosis
Kumar, R. K. (2005) · Humana Press eBooks · doi:10.1385/1-59259-940-0:179 · Cited by 17
Terakado, M., Suzuki, H., Hashimura, K., Tanaka, M., Ueda, H., Hirai, K., Asada, M., Ikura, M., Matsunaga, N., Saga, H., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00383 · Cited by 15
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities
Cruwys, S., Hein, P., Humphries, B., & Black, D. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.019 · Cited by 15
Ramasamy, S., Petha, C., Tendulkar, S., Maity, P., Eastgate, M. D., & Vaidyanathan, R. (2018) · Organic Process Research & Development · doi:10.1021/acs.oprd.8b00163 · Cited by 14
Murphy, B., Sum, C. S., Wang, T., Heiry, R., Kalinowski, S. S., Hung, C.-P., Chu, C.-H., Azzara, A. V., Ziegler, M., Burns, L., et al. (2019) · doi:10.1183/13993003.congress-2019.pa5383 · Cited by 11
Self-citationSakamoto, K., Noguchi, Y., Ueshima, K., Yamakuni, H., Ohtake, A., Sato, S., Ishizu, K., Hosogai, N., Kawaminami, E., Takeda, M., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.247908 · Cited by 9
Martusewicz-Boros, M. M., & Górska, K. (2020) · Advances in respiratory medicine · doi:10.5603/arm.a2020.0190 · Cited by 7
Synthesis and conformation of some 2,4-dioxa- and 2,4-dioxa-3-silabicyclo[3.3.1]nonanes
Peters, J. A., Cranenburgh, P. E. J. P.-V., Bovée, W. M. M. J., Rozema, H. P., TOORN, J. M. V. D., WORTEL, T. M., & van Bekkum, H. (1982) · Tetrahedron · doi:10.1016/0040-4020(82)80072-0 · Cited by 6
Tirucherai, G., Yu, D., Revankar, R., Klinger, G., Van Lier, J. J., Taubel, J., & Correll, T. (2019) · Rare ILD/DPLD · doi:10.1183/13993003.congress-2019.pa1398 · Cited by 6
Self-citationRosen, G., Sivaraman, L., Cheng, P. T. W., Murphy, B., Chadwick, K. D., Lehman‐McKeeman, L. D., Christian, R., & Gill, M. W. (2017) · doi:10.1183/1393003.congress-2017.pa1038 · Cited by 5
Self-citationDirect Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
Liao, S., Eickelberg, O., Schmidt, E. P., & Yang, Y. (2019) · Journal of Visualized Experiments · doi:10.3791/59450 · Cited by 5
Self-citation
Cited by
An Analysis of Successful Hit-to-Clinical Candidate Pairs
Brown, D. G. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00521 · Cited by 63
Gill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
Self-citationCheng, X., Jiang, S., Pan, B., Xie, W., & Meng, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01964-3 · Cited by 40
Base‐Modulated 1,3‐Regio‐ and Stereoselective Carboboration of Cyclohexenes
Kong, W., Bao, Y., Lu, L., Han, Z., Zhong, Y., Zhang, R., Li, Y., & Yin, G. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202308041 · Cited by 34
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 29
“A phase I trial of BBT-877 in 80 healthy volunteers resulted in only mild AEs and no serious AEs [87].”
Background
Metadata
- Authors
- Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., Dhanusu, S., Reddigunta, R., Kumaravel, S., Jusuf, S., Smith, D., Krishnananthan, S., Li, J., Wang, T., Heiry, R., Sum, C. S., Kalinowski, S. S., Hung, C.-P., Chu, C.-H., Azzara, A. V., Ziegler, M., Burns, L., Zinker, B. A., Boehm, S., Taylor, J., Sapuppo, J., Mosure, K., Everlof, G., Guarino, V., Zhang, L., Yang, Y., Ruan, Q., Xu, C., Apedo, A., Traeger, S. C., Cvijic, M. E., Lentz, K. A., Tirucherai, G., Sivaraman, L., Robl, J., Ellsworth, B. A., Rosen, G., Gordon, D. A., Soars, M. G., Gill, M., & Murphy, B. J.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Biocon-Bristol Myers Squibb Research & Development Center, Bangalore 560099, India
- Cardiovascular & Fibrosis Discovery Biology, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
- Corresponding author
- Cheng, Peter T. W.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-28
- Volume
- 64
- Issue
- 21
- Pages
- 15549-15581
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3209712727
- Cited by
- 61
- References
- 75
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 23 · 2023: 13 · 2022: 3 · 2021: 2
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- LPAR1, pulmonary fibrosis, structure-activity relationship, pharmacokinetics, ADME, drug discovery
- MeSH terms
- Animals, Dose-Response Relationship, Drug, Male, Pulmonary Fibrosis, Structure-Activity Relationship, Molecular Structure, Rats, Sprague-Dawley, Receptors, Lysophosphatidic Acid, Mice, Rats, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.